Acorda Therapeutics (ACOR) Surges After FAMPYRA Backed in Europe
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Join SI Premium – FREE
Shares of Acorda Therapeutics, Inc. (Nasdaq: ACOR) are surging after the company and Biogen Idec (NASDAQ: BIIB) announced that FAMPYRA has been granted a positive opinion for conditional approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Biogen Idec expects that a conditional marketing authorization for FAMPYRA should be granted within 67 days.
Marketing Approval in Europe Would Trigger $25 Million Payment to Acorda from Biogen Idec.
Shares of Acorda Therapeutics are surging 25% in pre-open trade to $33.34.
Biogen Idec expects that a conditional marketing authorization for FAMPYRA should be granted within 67 days.
Marketing Approval in Europe Would Trigger $25 Million Payment to Acorda from Biogen Idec.
Shares of Acorda Therapeutics are surging 25% in pre-open trade to $33.34.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
- FDA clears Adicet Bio IND application for prostate cancer therapy
- FDA approves Moderna's updated 2026-2027 COVID-19 vaccines
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
